We're raising our price target on Eli Lilly as the GLP-1 leader delivers a huge beat

CNBC Published Updated Stocks
Sign in to save

Why it matters

Eli Lilly's GLP-1 drugs have exceeded $1 billion in combined sales, with both Zepbound and Mounjaro showing triple-digit growth, leading to a raised price target.

Article tone

Neutral How the article is written, as reported by the source.

Expected market reaction

Bullish Confidence 90% How confidence is read Horizon: Short term Impact: Moderate

Market impact analysis based on bullish sentiment with 90% confidence.

Evidence trail

Evidence
Source CNBC
Claim We're raising our price target on Eli Lilly as the GLP-1 leader delivers a huge beat
AI inference Bullish · 90%
Generated 2026-02-04 19:45

AI provenance

Analysed by Llama 3.1 8B Instant (Groq) Methodology v1.0 Generated
Technical identifiers
Provider tag
groq-llama-3.1-8b-instant
Analysis version
groq-llama-3.1-8b-instant
Article id
41658

Original source

Combined sales for the company's blockbuster GLP-1 drugs Zepbound and Mounjaro exceeded $1 billion, with each showing triple-digit growth.

Read the full article on CNBC

Original article published by CNBC on February 4, 2026. Analysis and insights provided by AnalystMarkets AI.

Related coverage